Whooping cough (suspected)
BioMG follows French guidelines. Adapt it to the guidelines and the tests available where you practise.
Cough < 21 days, paroxysmal with apnoea in an unvaccinated child
Laboratory tests
- Bordetella NAAT (PCR) on nasopharyngeal sample (pertussis PCR) + culture if symptoms for less than 15 days
- State on the prescription the vaccination status (date of the last dose) and how long the cough has lasted: information required by the French laboratory fee schedule for the PCR.
Cough < 21 days, lasting more than 7 days (or pertussis contact); nocturnal paroxysms and/or whoop and/or post-tussive vomiting and/or cyanosis, apnoea
Laboratory tests
- Bordetella NAAT (PCR) on nasopharyngeal sample (pertussis PCR) + culture if symptoms for less than 15 days
- State on the prescription the vaccination status (date of the last dose) and how long the cough has lasted: information required by the French laboratory fee schedule for the PCR.
Cough > 21 days
- No further tests after 21 days of symptoms.
Whooping cough contact
Laboratory tests
- Bordetella NAAT (PCR) on nasopharyngeal sample (pertussis PCR) if symptomatic
- State on the prescription the vaccination status (date of the last dose) and how long the cough has lasted: information required by the French laboratory fee schedule for the PCR.
Prolonged cough in adults (more than 3 weeks, chronic beyond 8 weeks): no laboratory tests
- No routine laboratory tests. Initial work-up of a chronic cough: recent chest X-ray and spirometry.
Do not order
- Pertussis PCR in an adult coughing for more than 3 weeks: not indicated as first line, as it is very likely to be already negative; rather sample a recent secondary case among contacts [6]; the NABM excludes it beyond 3 weeks [2].
- Pertussis serology: removed from the NABM since 15 February 2011, it should no longer be used for routine diagnosis [6].
- Routine FBC “for eosinophils”: no solid evidence justifies measuring blood eosinophils routinely in chronic cough, or to predict the response to corticosteroids [7].
Sources (15)
- Santé publique France. Coqueluche en France. Point au 18 septembre 2024 (données au 16 septembre 2024).
- Caisse nationale de l’assurance maladie. Nomenclature des actes de biologie médicale (NABM), version 105 : chapitre 19, Bordetella pertussis (préambule) et acte 5258.
- UK Health Security Agency. National pertussis guidance for England. Mai 2026.
- NSW Health (Nouvelle-Galles du Sud, Australie). Pertussis control guideline for public health units. Dernière mise à jour le 23 janvier 2015.
- UK Health Security Agency. Testing for pertussis in primary care. Mai 2026 (document joint à « Pertussis: guidelines for public health management », gov.uk).
- Conduite à tenir autour d’un ou plusieurs cas de coqueluche
- Morice AH, Millqvist E, Bieksiene K, et al. ERS guidelines on the diagnosis and treatment of chronic cough in adults and children. Eur Respir J. 2020;55(1):1901136.
- Irwin RS, French CL, Chang AB, Altman KW; CHEST Expert Cough Panel. Classification of Cough as a Symptom in Adults and Management Algorithms: CHEST Guideline and Expert Panel Report. Chest. 2018;153(1):196-209.
- Fiche CMG 2024 - Alerte coqueluche !
- Santé Publique France - Coqueluche 2014
- CDC - Pertussis (présentation clinique)
- Définition de coqueluche pour les CDC
- Baxter, R., Bartlett, J., Fireman, B., Lewis, E., & Klein, N. P. (2017). Effectiveness of vaccination during pregnancy to prevent infant pertussis. Pediatrics, 139(5).
- ECDC - Coqueluche
- DGS Urgent Juin 2024 - Coqueluche